2014-2015年ESBLs阳性和ESBLs阴性大肠埃希菌临床分布及其耐药性的分析

目的 分析2014-2015年产超广谱β-内酰胺酶(ESBLs)大肠埃希菌和ESBLs阴性大肠埃希菌的临床分布和耐药性.方法 收集2014年1月至2015年12月临床送检的4 721份标本,采用VITEK 2-Compact全自动细菌鉴定及药敏分析仪对大肠埃希菌进行分离和鉴定.结果 4 721份标本中检出大肠埃希菌1 181株,检出率为25.02%,2014、2015年大肠埃希菌的检出率分别为17.38%、19.24%,其中ESBLs阳性大肠埃希菌的检出率分别为44.46%、51.71%,增长7.25%.ESBLs阳性大肠埃希菌主要来源为尿液、痰液、血液、阑尾内容物、脓液和分泌物标本,主要感染科室是普外科、呼吸科、泌尿外科和神经外科等.ESBLs阴性大肠埃希菌的主要来源为尿液、血液、痰液、阑尾内容物、脓液和分泌物标本.2014-2015年大肠埃希菌的耐药率呈明显上升趋势,对阿米卡星、亚胺培南和美罗培南的敏感率较高.结论 大肠埃希菌的检出率2015年有所增加,其耐药性逐渐增强,需结合实际的药物敏感分析情况,选择合适的抗菌药物,降低耐药率,规范临床抗菌药物的使用.

Clinical distribution and drug resistance of ESBLs-producing and non ESBLs-producing Escherichia coli isolated from 2014 to 2015

Objective To analyze clinical distribution and drug resistance of extended-spectrum β-lactamase(ESBLs)-producing and non ESBLs-producing Escherichia coli(E.coli) isolated from 2014 to 2015.Methods Collected 4 721 clinical specimens from January 2014 to December 2015,separated and identified by using VITEK 2-Compact automatic microorganism identification and sensitivity analysis system of Biomerieux,France.Results A total of 1 181 E.coli were isolated from 4 721 clinical specimens,the isolation rate was 25.02%,and the isolation rates of 2014 and 2015 were 17.38% and 19.24% respectively.Meanwhile,the isolation rates of ESBLs-producing E.coli from 2014 and 2015 were 44.46% and 51.71%,increased 7.25%.For the ESBLs-producing E.coli,the main specimens from urine,sputum,blood,appendix content,pus and secreta,and general surgery department,pneumology department,urology,Neurosurgery departments were the main infection departments.For the non ESBLs-producing E.coli,the main specimens from urine,blood,sputum,appendix content,pus and secreta.The drug resistance of E.coli to antibiotics showed increasingly upward trend from 2014 to 2015.However,it showed high sensitive to amikacin,imipenem and meropenem.Conclusion As the isolation rate of E.coli increased in 2015,so does the drug resistance,and it is need combine with the actual situation of medication to regulate the usage of antibiotics.